MA

Mainz BioMed N.V.

Develops at-home diagnostic tests for the early detection of life-threatening cancers.

F

Overview

Corporate Details

ISIN(s):
NL0015000LC2 (+3 more)
LEI:
894500XWJE7LIJNYQ547
Country:
Germany
Address:
Robert-Koch-Strasse 50, 55129 Mainz
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mainz BioMed N.V. is a molecular genetics company that develops and commercializes market-ready in-vitro diagnostic (IVD) solutions for the early detection of life-threatening conditions. The company's flagship product, ColoAlert®, is a non-invasive, at-home screening test for colorectal cancer (CRC) marketed in Europe. Mainz BioMed is also advancing its product pipeline with proprietary genetic testing methods for other deadly conditions, including pancreatic cancer, to provide accessible and reliable early detection solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-15 15:01
Regulatory News Service
Mainz Biomed to Attend 2025 Maxim Growth Summit
English 10.2 KB
2025-10-08 15:00
Regulatory News Service
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel …
English 12.2 KB
2025-09-30 14:01
Regulatory News Service
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Sc…
English 12.1 KB
2025-09-23 14:01
Regulatory News Service
Mainz Biomed Announces Commercial Launch of ColoAlert in Switzerland
English 11.5 KB
2025-09-02 14:01
Regulatory News Service
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
English 11.2 KB
2025-08-13 14:01
Regulatory News Service
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert
English 11.6 KB
2025-07-23 14:01
Business and Financial Review
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for…
English 11.2 KB
2025-07-15 14:01
Earnings Release
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colore…
English 15.5 KB
2025-06-25 14:01
Regulatory News Service
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Scr…
English 11.1 KB

Automate Your Workflow. Get a real-time feed of all Mainz BioMed N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mainz BioMed N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mainz BioMed N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom VLG
Vetoquinol SA Logo
Develops and markets veterinary drugs and products for companion animals and livestock worldwide.
France VETO
Vifor Pharma AG Logo
A global leader in specialty pharmaceuticals for iron deficiency and nephrology.
Switzerland VIFN
ViGenCell Inc. Logo
Developing T-cell immune therapies to treat cancer and other incurable diseases.
South Korea 308080
Virbac Logo
Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.
France FR000
ViroGates A/S Logo
Develops suPAR diagnostic tests for inflammation risk assessment in acute care and longevity.
Denmark VIRO
Vistin Pharma Logo
A leading global producer of Metformin Hydrochloride for the global healthcare market.
Norway VISTN
Vita 34 AG Logo
A cell bank storing umbilical cord stem cells as biological insurance for families' future health.
Germany V3V
Vivoryon Therapeutics N.V. Logo
Developing first-in-class small molecule therapies for age-related and kidney diseases.
Germany VVY
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea 082800

Talk to a Data Expert

Have a question? We'll get back to you promptly.